Day: June 22, 2023

First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroups Noninvasive imaging and biomarker data support findings on liver biopsy and demonstrate broad treatment response to resmetirom Further analyses of results reinforce resmetirom safety and tolerability profile Company to host an investor event and webcast on Saturday, June 24 at 6:30 PM CEST / 12:30 PM ETCONSHOHOCKEN, Pa., June 22, 2023 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today presents resmetirom Phase 3 MAESTRO-NASH data at the opening general session of the European Association for the Study of the Liver Congress (EASL 2023). In December 2022, Madrigal...

Dr. Ivor John described how countries are rapidly investing in infrastructure and incentives for hydrogen fuels SANTA CLARITA, Calif., June 22, 2023 (GLOBE NEWSWIRE) — NewHydrogen, Inc. (OTC:NEWH), the developer of a breakthrough technology to produce low-cost green hydrogen, today announced that in a recent podcast the Company’s CEO, Steve Hill, and industry expert Dr. Ivor John discussed the future of hydrogen fuel and how the world is rapidly moving toward adoption. During the podcast, Dr. John explained how hydrogen is the fuel of the future, “Every day now hydrogen seems to be in the news. We have 50 countries that have developed hydrogen strategies and that number is increasing every month and every year.” Dr. John has been an advisor and partner with several hydrogen companies. He is an expert in hydrogen and has been a...

The general meeting of AS Trigon Property Development decided to elect Aivar Kempi as a new member of the Supervisory Board starting from 21.06.2023 for the next five (5) years, replacing Alo Lepp (deceased). AS Trigon Property Development’s Supervisory Board continues with three members: Joakim Johan Helenius (chairman), Torfinn Losvik and Aivar Kempi. Aivar Kempi (born 24.09.1958) has obtained an industial civil engineer degree from Tallinn University of Technology and has worked in real estate sector for over 30 years. Among other things, he has been the development division director at AS Merko Ehitus (1997-2005) and the head of the real estate department at AS Trigon Capital (2005-2018). Since 2018, Aivar Kempi has been offering independent real estate development advisory services through AKPC OÜ, of which he is also a member...

EDF announces the success of its senior multi-tranche bond issue for a nominal amount of ¥33 billion On 22 June 2023: EDF (AA stable JCR / BBB stable S&P / Baa1 stable Moody’s / BBB+ stable Fitch) successfully priced a senior Samurai bond issuance in 4 tranches for a nominal amount of ¥33 billion:¥25.3 billion bond, with a 5-year maturity and a 1.059% fixed coupon; ¥2.2 billion bond, with a 7-year maturity and a 1.355% fixed coupon; ¥4.4 billion bond, with a 10-year maturity and a 1.695% fixed coupon. ¥1.1 billion bond, with a 20-year maturity and a 2.328% fixed coupon.These transactions enable the Group to further strengthen the structure of its balance sheet, as well as refinance upcoming maturities. This transaction with a number of Japanese investors further contributes towards the Group’s investor base diversification policy. This...

Sale of the remainder of Casino’s stake in Assaí Paris, 22 June 2023 In order to strengthen its liquidity, Casino Group has launched today the sale of its residual stake in Assaí for 57,582,850 common shares, representing 11.7% of Assaí’s share capital. The sale will be implemented through an accelerated book building, executed by the Sao Paulo stock exchange (B3), in accordance with the applicable rules on this market place. Casino will inform the market of the result of such process. This communication is for informative purposes only under the current applicable laws and regulations, and is neither an offer to sell nor a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration...

FL Entertainment creates ‘Banijay Events’ & appoints François de Brugada as CEO Paris, 22 June 2023: FL Entertainment, a global entertainment leader, announces the creation of “Banijay Events”, a live events offering which will capitalise on the company’s expertise and success in content production, as well as expand its capabilities within the wider entertainment industry. The newly developed offering will be led by current Chief Executive Officer of Banijay France, François de Brugada. This announcement follows FL Entertainment’s recent new ventures – an investment into The Independents, and the acquisition of Balich Wonder Studio by Banijay. These investments in the events business, combined with the creation of Banijay Events, showcase FL Entertainment’s ambition to become a global leader in the production of live events. The...

WISeKey Meets All WebTrust Requirements for Its OISTE/WISeKey Root of Trust Geneva and Zug Switzerland – June 22, 2023 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions, today announces the attainment of the WebTrust seal of assurance, having met all the audit requirements for its OISTE/WISeKey Root of Trust. This critical achievement reinforces WISeKey’s commitment to adhering to the highest standards in cybersecurity and data integrity. WebTrust, a comprehensive evaluation standard jointly developed by the American Institute of Certified Public Accountants (AICPA) and the Canadian Institute of Chartered Accountants (CICA), conducts rigorous annual audits to assess the adequacy and effectiveness of controls deployed by Certification...

Potential first-line treatment for interstitial cystitis/bladder pain syndrome (IC/BPS) Global opportunity with a patient population of at least 6 million in the U.S. alone1Liège, Belgium – 22 June 2023 – 7AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of AlenuraTM, comparing the product candidate to both of its individual components (heparin and lidocaine)3 as well as placebo. AlenuraTM is a patented, innovative, clinical-stage bladder instillation product candidate that combines lidocaine, a well-established anaesthetic, in a new alkalinized form with heparin, a glycoso-amino-glycan (GAG),...